Daiichi Sankyo and Glycotope reach agreement for “first-in-class” ADC 03-Aug-2018 By Maggie Lynch Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate that enables tumor-specific binding to TA-MUC1.